Literature DB >> 18642036

Reproducibility and specificity concerns associated with nucleic acid amplification tests for detecting Chlamydia trachomatis.

A Hadgu1, M Sternberg.   

Abstract

Commercial nucleic acid amplification tests (NAATs) have become one of the most frequently used tests for detecting Chalmydia trachomatis. However, published studies have raised important concerns regarding the NAAT evaluation process in general and their reproducibility and clinical specificity in particular. This is because for many infectious diseases including chlamydia, a true gold standard simply does not exist and, as a result, estimation of test performance parameters in the absence of a gold standard is a difficult and challenging task. In this manuscript, we will attempt to address some issues pertaining to the evaluation of NAATs including NAAT reproducibility, test validity, and the manner in which positive NAAT results are confirmed. Finally, we will discuss some of the potential clinical and public health implications of testing by NAATs.

Entities:  

Mesh:

Year:  2008        PMID: 18642036     DOI: 10.1007/s10096-008-0586-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  24 in total

1.  One gene and one outcome? No way.

Authors:  Stephen Chanock; Sholom Wacholder
Journal:  Trends Mol Med       Date:  2002-06       Impact factor: 11.951

2.  False-positive gonorrhea test results with a nucleic acid amplification test: the impact of low prevalence on positive predictive value.

Authors:  Alan R Katz; Paul V Effler; Roy G Ohye; Barbara Brouillet; Maria Veneranda C Lee; Peter M Whiticar
Journal:  Clin Infect Dis       Date:  2004-02-27       Impact factor: 9.079

3.  Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection.

Authors:  Matthew R Golden; William L H Whittington; H Hunter Handsfield; James P Hughes; Walter E Stamm; Matthew Hogben; Agnes Clark; Cheryl Malinski; Jennifer R L Helmers; Katherine K Thomas; King K Holmes
Journal:  N Engl J Med       Date:  2005-02-17       Impact factor: 91.245

Review 4.  Evaluation of diagnostic tests without gold standards.

Authors:  S L Hui; X H Zhou
Journal:  Stat Methods Med Res       Date:  1998-12       Impact factor: 3.021

5.  Detection of Chlamydia trachomatis by nucleic acid amplification testing: our evaluation suggests that CDC-recommended approaches for confirmatory testing are ill-advised.

Authors:  Julius Schachter; Joan M Chow; Holly Howard; Gail Bolan; Jeanne Moncada
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

6.  Retesting and follow-up of first-catch urines from men yield variable results with three Chlamydia trachomatis nucleic acid amplification tests.

Authors:  S A Nordbø; K Lund; F E Skjeldestad
Journal:  APMIS       Date:  2000-11       Impact factor: 3.205

Review 7.  Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  Robert L Cook; Shari L Hutchison; Lars Østergaard; R Scott Braithwaite; Roberta B Ness
Journal:  Ann Intern Med       Date:  2005-06-07       Impact factor: 25.391

8.  The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection.

Authors:  Robert C Brunham; Babak Pourbohloul; Sunny Mak; Rick White; Michael L Rekart
Journal:  J Infect Dis       Date:  2005-10-10       Impact factor: 5.226

9.  Accuracy of results obtained by performing a second ligase chain reaction assay and PCR analysis on urine samples with positive or near-cutoff results in the LCx test for Chlamydia trachomatis.

Authors:  S Castriciano; K Luinstra; D Jang; J Patel; J Mahony; J Kapala; M Chernesky
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

10.  Reproducibility of positive test results in the BDProbeTec ET system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  Elizabeth E Culler; Angela M Caliendo; Frederick S Nolte
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

View more
  2 in total

1.  Chlamydia trachomatis test-of-cure cannot be based on a single highly sensitive laboratory test taken at least 3 weeks after treatment.

Authors:  Nicole H T M Dukers-Muijrers; Servaas A Morré; Arjen Speksnijder; Marianne A B van der Sande; Christian J P A Hoebe
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

2.  Pelvic inflammatory disease risk following negative results from chlamydia nucleic acid amplification tests (NAATs) versus non-NAATs in Denmark: A retrospective cohort.

Authors:  Bethan Davies; Katy M E Turner; Thomas Benfield; Maria Frølund; Berit Andersen; Henrik Westh; Helen Ward
Journal:  PLoS Med       Date:  2018-01-02       Impact factor: 11.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.